To address a possible role of HLA-E in MS, we initially examined its surface expression on resting CD4+ cells from healthy controls (HC), relapsing-remitting (MS-RR) and primary progressive (MS-PP) MS patients (Fig. 1A). Here, CD4 is linked to myeloid sarcoma.